Literature DB >> 19605492

Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.

Delphine Sauce1, Martin Larsen, Rachel J M Abbott, Andrew D Hislop, Alison M Leese, Naeem Khan, Laura Papagno, Gordon J Freeman, Alan B Rickinson.   

Abstract

In immunocompetent individuals, the stability of the herpesvirus-host balance limits opportunities to study the disappearance of a virus-specific CD8(+) T-cell response. However, we noticed that in HLA-A 0201-positive infectious mononucleosis (IM) patients undergoing primary Epstein-Barr virus (EBV) infection, the initial CD8 response targets three EBV lytic antigen-derived epitopes, YVLDHLIVV (YVL), GLCTLVAML (GLC), and TLDYKPLSV (TLD), but only the YVL and GLC reactivities persist long-term; the TLD response disappears within 10 to 27 months. While present, TLD-specific cells remained largely indistinguishable from YVL and GLC reactivities in many phenotypic and functional respects but showed unique temporal changes in two markers of T-cell fate, interleukin 7 receptor alpha (IL-7Ralpha; CD127) and programmed death 1 (PD-1). Thus, following the antigen-driven downregulation of IL-7Ralpha seen on all populations in acute IM, in every case, the TLD-specific population recovered expression unusually quickly post-IM. As well, in four of six patients studied, TLD-specific cells showed very strong PD-1 upregulation in the last blood sample obtained before the cells' disappearance. Our data suggest that the disappearance of this individual epitope reactivity from an otherwise stable EBV-specific response (i) reflects a selective loss of cognate antigen restimulation (rather than of IL-7-dependent signals) and (ii) is immediately preceded, and perhaps mediated, by PD-1 upregulation to unprecedented levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605492      PMCID: PMC2738242          DOI: 10.1128/JVI.00141-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Effector and memory T-cell differentiation: implications for vaccine development.

Authors:  Susan M Kaech; E John Wherry; Raft Ahmed
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

Review 2.  The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining.

Authors:  Victor Appay; Sarah L Rowland-Jones
Journal:  J Immunol Methods       Date:  2002-10-01       Impact factor: 2.303

Review 3.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  IL-15-independent proliferative renewal of memory CD8+ T cells in latent gammaherpesvirus infection.

Authors:  Joshua J Obar; Sarah G Crist; Erica K Leung; Edward J Usherwood
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

6.  Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection.

Authors:  Jianhong Cao; John McNevin; Uma Malhotra; M Juliana McElrath
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

7.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Authors:  Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-11-16       Impact factor: 25.606

Review 8.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides.

Authors:  A Gallimore; T Dumrese; H Hengartner; R M Zinkernagel; H G Rammensee
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

10.  Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

Authors:  P J Goulder; A K Sewell; D G Lalloo; D A Price; J A Whelan; J Evans; G P Taylor; G Luzzi; P Giangrande; R E Phillips; A J McMichael
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

View more
  11 in total

1.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

2.  Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults.

Authors:  Jaikumar Duraiswamy; Chris C Ibegbu; David Masopust; Joseph D Miller; Koichi Araki; Gregory H Doho; Pramila Tata; Satish Gupta; Michael J Zilliox; Helder I Nakaya; Bali Pulendran; W Nicholas Haining; Gordon J Freeman; Rafi Ahmed
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

3.  Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.

Authors:  Heather M Long; Alison M Leese; Odette L Chagoury; Shawn R Connerty; Jared Quarcoopome; Laura L Quinn; Claire Shannon-Lowe; Alan B Rickinson
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

4.  Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Authors:  Thomas C Greenough; Shalyn C Campellone; Robin Brody; Surbhi Jain; Victor Sanchez-Merino; Mohan Somasundaran; Katherine Luzuriaga
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

5.  A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection.

Authors:  Thomas C Greenough; Juerg R Straubhaar; Larisa Kamga; Eric R Weiss; Robin M Brody; Margaret M McManus; Linda K Lambrecht; Mohan Somasundaran; Katherine F Luzuriaga
Journal:  J Immunol       Date:  2015-09-28       Impact factor: 5.422

6.  CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Authors:  Rachel J M Abbott; Laura L Quinn; Alison M Leese; Harry M Scholes; Annette Pachnio; Alan B Rickinson
Journal:  J Immunol       Date:  2013-10-21       Impact factor: 5.422

7.  Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.

Authors:  Kazushi Izawa; Emmanuel Martin; Claire Soudais; Julie Bruneau; David Boutboul; Rémy Rodriguez; Christelle Lenoir; Andrew D Hislop; Caroline Besson; Fabien Touzot; Capucine Picard; Isabelle Callebaut; Jean-Pierre de Villartay; Despina Moshous; Alain Fischer; Sylvain Latour
Journal:  J Exp Med       Date:  2016-12-23       Impact factor: 14.307

8.  Evaluating cellular polyfunctionality with a novel polyfunctionality index.

Authors:  Martin Larsen; Delphine Sauce; Laurent Arnaud; Solène Fastenackels; Victor Appay; Guy Gorochov
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

9.  Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.

Authors:  Daniela F Angelini; Barbara Serafini; Eleonora Piras; Martina Severa; Eliana M Coccia; Barbara Rosicarelli; Serena Ruggieri; Claudio Gasperini; Fabio Buttari; Diego Centonze; Rosella Mechelli; Marco Salvetti; Giovanna Borsellino; Francesca Aloisi; Luca Battistini
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

10.  Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.

Authors:  Jo A Tucker; Caroline Jochems; James L Gulley; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancers (Basel)       Date:  2012-12-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.